Zhejiang Huahai Pharmaceutical
Market Cap
CN¥35.4b
Last Updated
2020/05/29 14:59 UTC
Data Sources
Company Financials +
Executive Summary
Zhejiang Huahai Pharmaceutical Co., Ltd. operates as a pharmaceutical company in China and internationally.
Rewards
Risk Analysis
+ 1 more risk
Snowflake Analysis
Adequate balance sheet with proven track record.
Similar Companies
Share Price & News
How has Zhejiang Huahai Pharmaceutical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 600521's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
1.5%
600521
-2.5%
CN Pharmaceuticals
0.6%
CN Market
1 Year Return
92.7%
600521
23.6%
CN Pharmaceuticals
9.1%
CN Market
Return vs Industry: 600521 exceeded the CN Pharmaceuticals industry which returned 23.8% over the past year.
Return vs Market: 600521 exceeded the CN Market which returned 8.4% over the past year.
Shareholder returns
| 600521 | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.5% | -2.5% | 0.6% |
| 30 Day | -0.3% | 1.5% | 2.8% |
| 90 Day | 28.4% | 7.2% | -0.5% |
| 1 Year | 92.7%92.7% | 25.1%23.6% | 10.8%9.1% |
| 3 Year | 59.8%57.6% | 14.4%10.5% | 2.5%-1.9% |
| 5 Year | 29.2%25.9% | -25.9%-29.6% | -40.1%-43.5% |
Price Volatility Vs. Market
How volatile is Zhejiang Huahai Pharmaceutical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Zhejiang Huahai Pharmaceutical undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 600521 (CN¥26.78) is trading below our estimate of fair value (CN¥80.38)
Significantly Below Fair Value: 600521 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 600521 is poor value based on its PE Ratio (52.8x) compared to the Pharmaceuticals industry average (37x).
PE vs Market: 600521 is poor value based on its PE Ratio (52.8x) compared to the CN market (36.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 600521's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 600521 is overvalued based on its PB Ratio (6.1x) compared to the CN Pharmaceuticals industry average (2.6x).
Next Steps
Future Growth
How is Zhejiang Huahai Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
24.3%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Zhejiang Huahai Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Check out Zhejiang Huahai Pharmaceutical's track record over time to understand how much the company has returned to shareholders and its earnings growth rate in the past.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
Past Performance
How has Zhejiang Huahai Pharmaceutical performed over the past 5 years?
-0.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 600521 has high quality earnings.
Growing Profit Margin: 600521's current net profit margins (11.4%) are higher than last year (1.6%).
Past Earnings Growth Analysis
Earnings Trend: 600521's earnings have declined by -0.6% per year over the past 5 years.
Accelerating Growth: 600521's earnings growth over the past year (691.6%) exceeds its 5-year average (-0.6% per year).
Earnings vs Industry: 600521 earnings growth over the past year (691.6%) exceeded the Pharmaceuticals industry 6.7%.
Return on Equity
High ROE: 600521's Return on Equity (11.6%) is considered low.
Next Steps
Financial Health
How is Zhejiang Huahai Pharmaceutical's financial position?
Financial Position Analysis
Short Term Liabilities: 600521's short term assets (CN¥5.0B) exceed its short term liabilities (CN¥2.7B).
Long Term Liabilities: 600521's short term assets (CN¥5.0B) exceed its long term liabilities (CN¥1.8B).
Debt to Equity History and Analysis
Debt Level: 600521's debt to equity ratio (49.2%) is considered high.
Reducing Debt: 600521's debt to equity ratio has increased from 21.9% to 49.2% over the past 5 years.
Debt Coverage: 600521's debt is well covered by operating cash flow (63.5%).
Interest Coverage: 600521's interest payments on its debt are well covered by EBIT (5x coverage).
Balance Sheet
Next Steps
Dividend
What is Zhejiang Huahai Pharmaceutical's current dividend yield, its reliability and sustainability?
0.75%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 600521's dividend (0.75%) is higher than the bottom 25% of dividend payers in the CN market (0.44%).
High Dividend: 600521's dividend (0.75%) is low compared to the top 25% of dividend payers in the CN market (1.96%).
Stability and Growth of Payments
Stable Dividend: 600521's dividend payments have been volatile in the past 10 years.
Growing Dividend: 600521's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (39.4%), 600521's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
CN¥2m
CEO Compensation
CEO
Bao Hua Chen (57yo)
no data
Tenure
CN¥2,017,200
Compensation
Mr. Bao Hua Chen serves as the President of TCM BU of Shanghai Pharmaceutical (group) Co., Ltd. Mr. Chen serves as General Manager and Director at Zhejiang Huahai Pharmaceutical Co., Ltd. Mr. Chen served a ...
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.7%.
Top Shareholders
Company Information
Zhejiang Huahai Pharmaceutical Co., Ltd.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Zhejiang Huahai Pharmaceutical Co., Ltd.
- Ticker: 600521
- Exchange: SHSE
- Founded: 1989
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CN¥35.413b
- Shares outstanding: 1.32b
- Website: https://www.huahaipharm.com
Number of Employees
Location
- Zhejiang Huahai Pharmaceutical Co., Ltd.
- Xunqiao
- Linhai
- Zhejiang Province
- 317024
- China
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 600521 | SHSE (Shanghai Stock Exchange) | Yes | Domestic Shares | CN | CNY | Mar 2003 |
| 600521 | XSSC (Shanghai Stock Exchange - Shanghai - Hong Kong Stock Connect) | Yes | Domestic Shares | CN | CNY | Mar 2003 |
Biography
Zhejiang Huahai Pharmaceutical Co., Ltd. operates as a pharmaceutical company in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products. It also engages in packaging components business, such as high-density polyethylene bottles and polypropylene caps. In addition, the company provides contract manufacturing and other services. Further, it is involved in import and export trade services. Pharmaceutical Co., Ltd. was founded in 1989 and is headquartered in Linhai, China.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/05/29 14:59 |
| End of Day Share Price | 2020/05/29 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.